Clinical Trial

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

Study acronym: VISTA-1

Recruiting Phase 2

Summary

RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2025-02-10; most recent amendment 2026-05-15.

Trial Details

NCT Number	NCT06824064
Lead Sponsor	Riboscience, LLC. Collaborators: Tam Anh Research Institute
Conditions	Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Enrollment	150 participants
Start Date	2025-01-17
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-18